Oxford Parkinson's Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Oxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.
Neuropathol Appl Neurobiol. 2018 Dec;44(7):722-736. doi: 10.1111/nan.12486. Epub 2018 May 8.
Gastrointestinal (GI) α-synuclein (aSyn) detection as a potential biomarker of Parkinson's disease (PD) is challenged by conflicting results of recent studies. To increase sensitivity and specificity, we applied three techniques to detect different conformations of aSyn in GI biopsies obtained from a longitudinal, clinically well-characterized cohort of PD patients and healthy controls (HC).
With immunohistochemistry (IHC), we used antibodies reactive for total, phosphorylated and oligomeric aSyn; with aSyn proximity ligation assay (AS-PLA), we targeted oligomeric aSyn species specifically; and with paraffin-embedded tissue blot (AS-PET-blot) we aimed to detect fibrillary, synaptic aSyn.
A total of 163 tissue blocks were collected from 51 PD patients (113 blocks) and 21 HC (50 blocks). In 31 PD patients, biopsies were taken before the PD diagnosis (Prodromal); while in 20 PD patients biopsies were obtained after diagnosis (Manifest). The majority of tissues blocks were from large intestine (62%), followed by small intestine (21%), stomach (10%) and oesophagus (7%). With IHC, four staining patterns were detected (neuritic, ganglionic, epithelial and cellular), while two distinct staining patterns were detected both with AS-PLA (cellular and diffuse signal) and with AS-PET-blot (aSyn-localized and pericrypt signal). The level of agreement between different techniques was low and no single technique or staining pattern reliably distinguished PD patients (Prodromal or Manifest) from HC.
Our study suggests that detection of aSyn conformational variants currently considered pathological is not adequate for the diagnosis or prediction of PD. Future studies utilizing novel ultrasensitive amyloid aggregation assays may increase sensitivity and specificity.
胃肠道 (GI) α-突触核蛋白 (aSyn) 作为帕金森病 (PD) 的潜在生物标志物的检测受到近期研究结果相互矛盾的挑战。为了提高敏感性和特异性,我们应用三种技术来检测从 PD 患者和健康对照者 (HC) 的纵向、临床特征良好的队列中获得的 GI 活检组织中不同构象的 aSyn。
通过免疫组织化学 (IHC),我们使用针对总、磷酸化和寡聚体 aSyn 的抗体;通过 aSyn 邻近连接测定 (AS-PLA),我们特异性地靶向寡聚体 aSyn 物种;通过石蜡包埋组织印迹 (AS-PET-blot),我们旨在检测纤维状、突触 aSyn。
从 51 名 PD 患者 (113 个组织块) 和 21 名 HC (50 个组织块) 共收集了 163 个组织块。在 31 名 PD 患者中,在 PD 诊断前 (前驱期) 进行了活检;而在 20 名 PD 患者中,在诊断后 (显性期) 进行了活检。大多数组织块来自大肠 (62%),其次是小肠 (21%)、胃 (10%) 和食管 (7%)。通过 IHC,检测到四种染色模式 (神经突、神经节、上皮和细胞),而通过 AS-PLA 和 AS-PET-blot 检测到两种不同的染色模式 (细胞和弥漫信号) 和 (aSyn 定位和隐窝信号)。不同技术之间的一致性水平较低,没有单一技术或染色模式能够可靠地区分 PD 患者 (前驱期或显性期) 和 HC。
我们的研究表明,目前认为病理性的 aSyn 构象变体的检测不足以用于 PD 的诊断或预测。未来利用新型超敏淀粉样蛋白聚集测定的研究可能会提高敏感性和特异性。